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Microbes occupy countless ecological niches in nature. Sometimes
these environments may be on or within another organism, as is
the case in both microbial infections and symbiosis of mammals.
Unlike pathogens that establish opportunistic infections, hundreds
of human commensal bacterial species establish a lifelong cohab-
itation with their hosts. Although many virulence factors of infec-
tious bacteria have been described, the molecular mechanisms
used during beneficial host–symbiont colonization remain almost
entirely unknown. The novel identification of multiple surface
polysaccharides in the important human symbiont Bacteroides
fragilis raised the critical question of how these molecules con-
tribute to commensalism. To understand the function of the
bacterial capsule during symbiotic colonization of mammals, we
generated B. fragilis strains deleted in the global regulator of
polysaccharide expression and isolated mutants with defects in
capsule expression. Surprisingly, attempts to completely eliminate
capsule production are not tolerated by the microorganism, which
displays growth deficits and subsequent reversion to express
capsular polysaccharides. We identify an alternative pathway by
which B. fragilis is able to reestablish capsule production and
modulate expression of surface structures. Most importantly, mu-
tants expressing single, defined surface polysaccharides are defec-
tive for intestinal colonization compared with bacteria expressing
a complete polysaccharide repertoire. Restoring the expression of
multiple capsular polysaccharides rescues the inability of mutants
to compete for commensalism. These findings suggest a model
whereby display of multiple capsular polysaccharides provides
essential functions for bacterial colonization during host–symbiont
mutualism.
bacterial symbiosis  Bacteroides fragilis  capsular polysaccharide 
intestinal microbiota
We live in a microbial world. Immediately upon birth,humans coordinately assemble a complex bacterial mi-
crobiota on almost all environmentally exposed surfaces (1).
Although it has been appreciated for decades that humans
harbor multitudes of commensal bacteria, recent studies have
begun to reveal the extraordinary diversity and complexity of the
ecosystem we provide to microorganisms. Advances in genomic
technologies have demonstrated that we harbor dozens of bac-
terial species in our stomachs, hundreds on our skin and oral
cavity, and thousands within our lower gastrointestinal tract
(2–4). The magnitude of these interactions and the evolutionary
forces that drive them must exert profound influences on the
biology of both microbe and man. The gastrointestinal tract
provides an excellent example of the complex interactions
between the microbiota and the host (5). Bacteria dominate this
biological niche, both numerically and in terms of diversity. Of
the multitudes of bacterial species that colonize the mammalian
gastrointestinal tract (1013 organisms from 1,000 different
species), those of the genus Bacteroides are among the most
numerically prominent in humans (6). For decades, bacteria have
been known to perform the essential function of metabolizing
complex carbohydrates subsequently used by their mammalian
hosts; Bacteroides species have been shown to be essential for this
function (7, 8). Analysis of the genome sequences of the human
Bacteroides (Bacteroides thetaiotaomicron, Bacteroides vulgatus,
Bacteroides distasonis, and Bacteroides fragilis) reveals that this
genus has evolved numerous glycosidases for carbohydrate deg-
radation (9). B. thetaiotaomicron induces carbohydrate decora-
tions of the intestinal epithelium to mediate the normal archi-
tectural development of host tissue (10). Furthermore, B. fragilis
was first described to produce multiple surface capsular poly-
saccharides (11). It has been recently revealed that all studied
Bacteroides contain numerous genomic loci for capsular poly-
saccharide production, a unique and distinguishing feature of
this genus of bacteria. Studies show that various Bacteroides
species share with their human host a mammalian-evolved
biochemical pathway for the addition of sugar modifications to
surface proteins and polysaccharides (12). Moreover, we have
recently demonstrated that B. fragilis elaborates an important
immunomodulatory polysaccharide that instructs the normal
development of the host immune system (13). Thus, the Bacte-
roides have dedicated a significant proportion of their biology to
the production and functions of capsular polysaccharides during
coevolution with mammals.
Decades of research have assigned various functions to surface
polysaccharides of pathogens, including biofilm production, tissue
adherence, and antiphagocytic activity during immune evasion (14).
Capsule production has been shown to be required for bacterial
virulence in numerous animal models of disease, and polysaccha-
rides are the key components of many vaccines developed to
prevent pathogenic bacterial infections (15, 16). Conversely, the
biologic significance of capsular polysaccharide production during
beneficial host–bacterial commensalism has only recently been
suggested (17). It is believed that the multiple capsular polysaccha-
rides (and perhaps other surface structures) of the Bacteroides
create systems for altering the physical properties of bacterial
surfaces (9). Several reports have predicted that the expression of
multiple capsular polysaccharides by B. fragilis provides functions
that are critical for host–bacterial symbiosis (11, 18, 19). However,
this notion currently remains without experimental corroboration.
In the report contained herein, we examine the role of capsular
polysaccharide production during the relationship between B.
fragilis and its mammalian host. By generating bacterial mutants in
the regulation of capsule expression, we find that production of at
least one capsular polysaccharide is required for the viability of the
microorganism.Most importantly, inhibiting the ability of B. fragilis
to modulate its surface architecture renders it unable to compete
for colonization of the gastrointestinal tract of animals. It appears
that Bacteroides have invested heavily in the development of
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dynamicmolecularmechanisms to establish andmaintain residence
within the mammalian ecosystem. These results provide the foun-
dation for understanding our evolutionary cohabitation with the
microbial world around and within us.
Results
Capsular Polysaccharide Expression Is Critical for B. fragilis.The eight
known capsular polysaccharide (CPS) biosynthesis loci of B.
fragilis are scattered throughout the genome as distinct polycis-
tronic operons of 11–22 genes (PSA–PSH) (18, 20). Mpi (mul-
tiple promoter invertase), a member of the serine site-specific
DNA recombinase family, acts as a global transcriptional regu-
lator of polysaccharide expression through inverting promoters
between the ‘‘on’’ and ‘‘off’’ orientations (Fig. 1A) (20). We
introduced a genomic mutation in the mpi gene by homologous
recombination in a PSA deletion background, because PSA is
the most abundantly expressed polysaccharide [produced by
79% of all bacterial cells in culture (11)]. We subsequently
screened mutants by PCR using promoter-specific primers to
isolate clones with all Mpi-regulated promoters in the ‘‘locked-
off’’ orientation. Similar to previous findings (20), cultures of
wild-type B. fragilis are heterogeneous with regard to polysac-
charide expression and are in phase variation displaying both
‘‘on’’ and ‘‘off’’ promoters [Fig. 1B and supporting information
(SI) Table 1]. Upon mutagenesis, we isolated one mutant
[B. fragilis CPM1 (capsular polysaccharide mutant)] with seven
of the eight characterized promoters in the ‘‘off’’ orientation at
the time of mpi deletion (PSC is not controlled by Mpi). When
mpi was introduced into CPM1 by transcomplementation, each
of the Mpi-controlled polysaccharide promoters regained the
ability to invert (Fig. 1B). We phenotypically verified the pres-
ence or absence of CPS synthesis with immunoblot analysis using
antisera specific for each molecule. A complete loss of polysac-
charide expression from all Mpi-controlled loci was observed in
strain CPM1 compared with wild-type B. fragilis (Fig. 1C).
Expression of the remaining known capsular polysaccharide
(PSC) in B. fragilis is predicted to not be controlled by promoter
inversion, although it shares other critical transcriptional regu-
latory elements with the seven Mpi-regulated CPS (11). Indeed,
immunoblot analysis showed an increase in PSC production for
CPM1 over that for wild-type cultures (Fig. 1C). Consistent with
this observation, PSC was expressed in 100% of cells for the Mpi
mutant strain CPM1 but in only 4.2% of wild-type cultures when
measured by flow cytometry with PSC-specific antiserum (Fig.
1D). Thus, expression of PSC appears to represent a default
mechanism for capsule expression in the absence of
Mpi-regulated polysaccharides.
Capsule Mutants Spontaneously Revert to Express Capsular Polysac-
charides.To characterize the role of polysaccharide production in
B. fragilis, we introduced a PSC deletion vector into CPM1 to
generate mutants defective in the production of PSC. The strain
bearing this deletion (named CPM2) unexpectedly showed a
dramatic defect in culture growth compared with that of wild-
type B. fragilis or the mutant strain CPM1, as assessed by optical
density and plating for colony-forming units (Fig. 2A and data
not shown). Furthermore, the mutant strain aggregated upon in
vitro growth in culture (SI Materials and Methods and SI Fig. 5).
As previously shown for B. fragilis and other organisms, the
absence of a capsule layer may expose surface adhesive mole-
cules leading to aggregation (21, 22). We next investigated the
possible mechanism(s) that may explain the growth attenuation
resulting from deletion of polysaccharide biosynthesis in B.
fragilis. When CPM2 was grown in laboratory culture media and
sequentially passaged for 5 days, we observed a progressive
restoration of growth (Fig. 2A). Furthermore, passaged cultures
displayed a recovery of CPS synthesis, as demonstrated by the
presence of high-molecular-weight species after immunoblot
analysis of whole-cell lysates using antisera raised against whole
bacteria (Fig. 2B). Thus, the absence of polysaccharide produc-
tion and the attenuation of growth are either genetically or
phenotypically linked, demonstrating the importance of poly-
saccharide molecules to B. fragilis. The 5-day-passaged strain
that exhibits wild-type growth characteristics may have acquired
a genetic mutation to overcome the selective pressure of a
growth defect; accordingly, we termed this revertant strain
CPM3.
Promoter Inversion Occurs in the Absence of Mpi. What mediates
polysaccharide expression in an mpi mutant strain? Initially, we
tested the hypothesis that alternate promoters directed in the
‘‘off’’ orientation may be driving transcription of capsular poly-
saccharides in CPM3. Promoter fusions to transcriptional re-
porters determined that ‘‘off’’-oriented promoters were incapa-
ble of mediating polysaccharide expression (SI Fig. 6). To
examine the possible existence of a pathway secondary to Mpi
that is capable of catalyzing promoter inversion, we screened the
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Fig. 1. Deletion of the global regulator of polysaccharide promoter inver-
sion in B. fragilis. (A) Schematic representing promoters flanked by inverted
repeats (IR) of polysaccharide biosynthesis loci. Mpi induces recombination at
the IR sites to invert promoters. Boxes below represent PCR products distin-
guishing ‘‘on’’ and ‘‘off’’ orientations. (B) PCR products generated from
chromosomal DNA of wild-type B. fragilis 9343, an isolated mpi mutant
(CPM1), and CPM1 strain complemented with the mpi gene (CPM1 pFD340-
mpi). Unlike wild-type, all Mpi-controlled capsular polysaccharide (CPS) pro-
moters are locked ‘‘off’’ in CPM1. Genetic rescue of mpi restores phase
variation in CPM1. (C) Immunoblot analysis demonstrates that expression of
PSC is not controlled by Mpi. Note the absence of all Mpi-regulated CPS and
the overexpression of PSC. (D) Flow cytometry analysis of surface CPS demon-
strates that all CPM1 cells express PSC (99.8%) compared with 4.2% in wild-
type cultured cells. Black histograms represent the control antibody; gray
histograms (-PSC) show PSC on the surface of B. fragilis CPM1.
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promoters of polysaccharide operons in CPM3 for their ‘‘on’’ or
‘‘off’’ orientation. We were surprised to observe that the pro-
moter upstream of the PSB biosynthesis locus displayed a
reversion to the ‘‘on’’ orientation in CPM3 (the mpi mutant
background), but only after PSC deletion (Fig. 2C Upper). Only
the PSB promoter reverted in 8 of 10 trials (PSD and PSH once
each); thus, there appears to be a requirement for production of
at least one capsular polysaccharide, with a strong (but not
absolute) bias for PSB production in the absence of Mpi.
Immunoblot analysis of whole-cell lysates using antiserum spe-
cific to PSB demonstrated the phenotypic production of PSB
(Fig. 2D). CPM3 exhibited recovery of all Mpi-regulated pro-
moter inversions whenmpiwas provided in trans (Fig. 2CLower).
To quantify the frequency of reversion, we used flow cytometry
to enumerate the proportion of bacteria expressing PSB on their
surfaces. Unlike wild-type cultures, in which only 7.4% of cells
in a mixed population express PSB, nearly all CPM3 revertants
assembled PSB as part of their bacterial envelopes (Fig. 2E). A
previously developed assay using cleavage of PCR products from
invertible promoters demonstrated that the PSB promoter in
strain CPM3 is found exclusively in the ‘‘on’’ orientation (SI Fig.
7) (11). Quantitative PCR digestion and flow cytometry showed
that every bacterial cell expresses PSB, thus strongly suggesting
that production of at least one capsular polysaccharide is essen-
tial for B. fragilis viability. This reversion resulting in the
expression of PSB occurred only after deletion of a non-Mpi-
controlled polysaccharide (PSC). A further link between the
expression of PSB and PSC was shown through the significant
increase in PSC-expressing bacteria upon deletion of only PSB
(B. fragilis 9343PSB), as measured by flow cytometry (SI Fig.
8). Taken together, these data demonstrate that B. fragilis has
developed a profound and unusual requirement for the produc-
tion of at least one capsular polysaccharide.
B. fragilis Employs Multiple Pathways for Capsular Polysaccharide
Expression. The finding that the PSB promoter reverted to the
‘‘on’’ orientation in CPM3 suggests that this strain acquires a
‘‘gain-of-function’’ phenotype to invert promoters under the
physiologic stress of multiple polysaccharide deletion. To test
whether CPM3 has the ability to catalyze promoter recombina-
tion in the absence ofmpi, we introduced a reporter plasmid with
the PSB promoter in the ‘‘off’’ orientation into several B. fragilis
strains. We measured inversion of the PSB promoter within the
plasmid from ‘‘off’’ to ‘‘on’’ orientation by PCR. The increased
activity of promoter inversion in CPM3 was evidenced by
recombination of the PSB promoter reporter, similar to the
function found in wild-type bacteria (Fig. 3A). CPM1, also
deleted inmpi but not displaying a selective pressure to revert to
polysaccharide production, is incapable of flipping the ‘‘off’’-
positioned PSB promoter. Furthermore, analysis of reporter
plasmids for the remaining polysaccharide promoters illustrates
that they are incapable of flipping to the ‘‘on’’ orientation in
CPM3 (SI Fig. 9), corroborating the specificity of CPM3’s
activity for the PSB promoter.
In addition to mpi, the genome sequence of the prototype B.
fragilis strain NCTC9343 has been shown to contain two other
serine site-specific recombinase genes: ssr1 and ssr3 (also known
as finB) (Fig. 3B) (19, 20). We hypothesized that one of these
homologues may serve the nonredundant function of catalyzing
recombination at invertible promoters in the absence of Mpi. To
determine whether either gene product could mediate promoter
inversion, we used reporter plasmids with the PSB promoter in
the ‘‘off’’ orientation that also expressed either Ssr1 or Ssr3.
These reporter constructs were subsequently introduced into B.
vulgatus, a related species previously shown to be incapable of
inverting the polysaccharide promoters of B. fragilis (20). As
demonstrated in Fig. 3C, Ssr1 was unable to mediate PSB
promoter inversion in B. vulgatus, as assessed by PCR. In
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Fig. 2. Phenotypic reversion of B. fragilis mutants defective in CPS production. (A) Growth curve of bacterial cultures after specific deletion of PSC from the
mpi mutant CPM1 shows severe growth attenuation of CPM2 (day1). A spontaneous reversion after serial passage of the bacterial cultures for 5 days restores
in vitro growth (CPM3 day5). (B) Immunoblot analysis shows the overall reduction in CPS production inmpimutant strains (CPM1 and CPM2) and the subsequent
stepwise increase in polysaccharide production in CPM3 coincident with growth restoration. (C) Promoter analysis of CPM3 after 5 days of passage demonstrates
that the PSB promoter undergoes reversion to the ‘‘on’’ orientation. CPM3 complemented with the mpi gene (CPM3 pFD340-mpi) displays restoration of phase
variation at every promoter. (D) Immunoblot analysis with specific antisera shows the loss of PSB expression in CPM1 and a spontaneous recovery of PSB
production under the selective pressure imposed by psc deletion (CPM2 day1). A phenotypic enrichment of PSB expression is found in CPM3. (E) Flow cytometry
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Liu et al. PNAS  March 11, 2008  vol. 105  no. 10  3953
M
IC
RO
BI
O
LO
G
Y
contrast, the expression of Ssr3 was sufficient to catalyze this
reaction. The ability of Ssr3 to facilitate promoter inversion is
consistent with the previous observation that this molecule binds
to invertible promoters upstream of polysaccharide biosynthesis
operons in B. fragilis (23).
We next investigated whether Ssr3 was capable of mediating
inversion of the other capsular polysaccharide promoters in mpi
deletion mutants. ssr3 was cloned into the expression vector
pFD340 and was ectopically overexpressed in CPM1 (with all
Mpi-regulated invertible promoters in the ‘‘locked-off’’ orien-
tation). As shown by PCR analysis using promoter-specific
primers, Ssr3 is capable of catalyzing recombination at all
Mpi-regulated invertible promoters in the absence of Mpi (Fig.
3D). The recovery of phase variation is also recapitulated in the
mutant strain CPM3 (SI Fig. 10). In addition to capsular
polysaccharides, it has been shown that Mpi regulates promoter
inversion at six additional genomic loci, the products of which all
encode for unknown proteins. Mpi is capable of catalyzing
promoter inversion at all of these sites; Ssr3 is able to flip five
of the six promoters, again demonstrating its ability to substitute
for the lack of Mpi (SI Fig. 11). None of these ORFs encode for
predicted surface proteins, and, unlike capsular polysaccharides,
none are affected by the deletion of PSC (data not shown).
Taken together, in addition to Mpi, we have revealed that a
second enzyme is capable of mediating promoter inversion in B.
fragilis and appears to provide a ‘‘fail-safe’’ function to ensure
production of capsular polysaccharides.
Mutants Expressing a Single Capsular Polysaccharide Are Defective
for Intestinal Colonization of Animals. It has been proposed that
control of multiple polysaccharide loci through promoter inver-
sion allows for the generation of extensive surface diversity
during bacterial colonization of the mammalian gastrointestinal
tract (11, 18, 19). We reasoned that if the purpose of this system
is to generate a multiplicity of surface structures (256 possible
combinations of the 8 known polysaccharides), the homoge-
neous polysaccharide-expressing strains of B. fragilis we have
created may display defects during colonization. Initially, germ-
free mice (animals born and raised in the absence of microbial
contamination) were readily colonized to similar levels by wild-
type and mutant strains upon monoassociation with bacteria
(Fig. 4A). Thus, all strains are competent for growth in animals.
However, germ-free animals provide a model for the direct
comparison of two bacterial strains for initial colonization
(mimicking the events after a sterile birth) and thus accurately
reflect each strain’s capacity for competitive colonization with-
out the confounding effects of a complete microbiota. We
coassociated germ-free animals with wild-type and mutant B.
fragilis strains and compared their ability to establish intestinal
colonization. Competition experiments between wild-type and
CPM1 strains demonstrated that wild-type B. fragilis quickly
outcompeted the single polysaccharide (PSC)-producing CPM1
strain in terms of intestinal colonization (Fig. 4B). After 7 days,
95% of the bacteria recovered from the competition experiment
in germ-free animals were wild-type organisms. Coculture of
wild-type bacteria with CPM1 during serial passage in laboratory
media consistently resulted in no growth defect at any time point
(Fig. 4C); this finding illustrates that the colonization phenotype
observed is due to factors found in the intestinal environment of
animals. The same phenotype for cocolonization is also ob-
served for CPM3, which expresses only PSB (SI Fig. 12), as well
as for a previously characterized PSA-only-expressing strain
mpi mut44 (data not shown) (20). Thus, expression of PSA,
PSB, or PSC alone is insufficient to allow bacterial competition
against wild-type B. fragilis.
We next sought to determine whether the colonization defect
for CPM1, a single-polysaccharide-producing mutant of B. fra-
gilis, could be reversed by restoring expression of the variable
surface polysaccharides with ectopic expression of either Mpi or
Ssr3. In competitive co-colonization experiments, CPM1 strains
complemented with Mpi or Ssr3 rapidly outcompeted the PSC-
only-producing mutant CPM1 (Fig. 4 D and E). This result
provides additional evidence that single-polysaccharide-
expressing B. fragilis mutants exhibit severe defects in host
colonization when challenged by the presence of a B. fragilis
strain that can vary its surface polysaccharide expression. In
summary, examinations within this article demonstrate that B.
fragilis has a strong propensity to elaborate at least one surface
polysaccharide for in vitro growth, and expression of a single
polysaccharide appears insufficient to allow bacterial coloniza-
tion of the mammalian host comparable with that by wild-type
bacteria.
Discussion
The intestinal microbiota of humans contains 10 times more cells
than the human body and 100 times the number of genes than the
human genome (24). Although we are beginning to understand
the identities of microorganisms that inhabit the gastrointestinal
tract, the mechanisms they use to establish colonization are
almost entirely unknown. The Bacteroides represent one of the
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Fig. 3. An Mpi-independent pathway for promoter inversion. (A) Upon
introduction of reporter plasmid pCK56 (containing the PSB promoter in the
‘‘off’’ orientation), wild-type B. fragilis and CPM3 are competent to mediate
conversion of the ‘‘off’’ promoter to the ‘‘on’’ position. CPM1 (mpi) lacks the
ability to invert the locked-off psb promoter. (B) Phylogenetic analysis dem-
onstrating the relatedness of the three serine site-specific recombinases (Ssr)
inB. fragilisNCTC9343 generated by CLUSTAL W analysis. The percent identity
values indicate direct sequence comparisons of Ssr3 and Ssr1 to Mpi, respec-
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most numerically prominent constituents of the human micro-
biota, and all members of this genus encode multiple capsule loci
and contain Mpi homologues (9). Are capsular polysaccharides
key molecular components that mediate various interactions
between symbiotic Bacteroides and their mammalian hosts? The
importance of these molecules is suggested by our finding that B.
fragilis requires expression of at least one capsular polysaccha-
ride for in vitro growth. When we selected for a mutant that was
genetically unable to express all seven Mpi-regulated polysac-
charides, we observed that every viable cell phenotypically
expressed the default polysaccharide PSC.When we deleted PSC
in this strain, we were able to recover only a poorly growing strain
that overcame its growth defect and reverted to express another
polysaccharide. To our knowledge, this is the first demonstration
that the lack of capsule expression adversely affects bacterial
growth. We demonstrate that B. fragilis contains an alternative
recombinase (Ssr3) that is capable of inverting polysaccharide
promoters. We were, however, unable to generate mutants of
Ssr3 (because it is present on a multicopy plasmid) to directly
assess whether it is responsible for the CPM3 phenotype. Also,
genomic sequencing of the PSB promoter or the ssr3 gene and
upstream regulatory elements yielded no mutations between any
of the CPM mutants and wild-type bacteria (data not shown).
Importantly, Ssr3 can compensate for the absence of Mpi in both
catalyzing promoter inversion and complementing defects in
animal colonization. An inhibition of growth upon capsule
deletion, a redundancy of mechanisms to ensure capsule bio-
synthesis, and defects in colonization upon limiting the capsular
polysaccharide repertoire attest to the evolutionary impor-
tance for regulation of surface architecture by B. fragilis during
colonization.
The bacterial cell envelope can be viewed as the structural
interface between microorganisms and their countless environ-
ments, mediating essential functions required for microbial
attachment and colonization (25). The many examples of ad-
herence mechanisms used by bacterial pathogens during infec-
tion includemolecules such as pili, fimbriae, and surface proteins
(26). However, mechanisms involved in the establishment of
colonization by multitudinous and important symbiotic organ-
isms remain largely uncharacterized. Pioneering work by Com-
stock and colleagues (11) first demonstrated that B. fragilis
contains at least eight distinct capsular polysaccharides; the
recent findings from genome sequences that three other Bacte-
roides species contain multiple capsule structures indicate that
this is a unique and distinguishing feature of these important
human commensals (9). We demonstrate that B. fragilis, a
numerically prominent symbiotic organism of the human micro-
biota, is attenuated for intestinal colonization when it can no
longer express a diverse repertoire of surface structures. Spe-
cifically, our data show that B. fragilis strains able to synthesize
only a single polysaccharide cannot compete with wild-type
bacteria for survival in the gastrointestinal tract of germ-free
animals. Restoration of surface diversity in these mutants
through complementation with either Mpi or its alternative
homolog, Ssr3, rescues defects in both capsular polysaccharide
production and intestinal colonization. All sequenced Bacte-
roides contain orthologs of Mpi, presumably to create extensive
surface diversity in these human commensals. Thus, our results
with the well studied model organism B. fragilis may extend to
other numerically significant commensal bacteria that inhabit
the gastrointestinal tract of humans. Because the gut presents a
dynamic and changing environment to colonizing organisms
(i.e., nutrient changes, immune responses, bacteriophage at-
tacks), perhaps sustained association of commensal bacteria
with mammals requires intricate and dynamic processes unlike
expression of a single toxin or adhesin used by many pathogens
to establish acute infections. The regulation of surface architec-
ture during intestinal colonization appears to be critically in-
volved for establishing the commensal association of B. fragilis
with its mammalian host. Recent efforts to define the ‘‘normal’’
sequence of colonization by bacterial species after birth have
resulted in a deeper understanding of the evolutionary partner-
ship between humans and their microbiota (27). Our findings
provide the framework to compel future studies to reveal the
mechanisms by which the bacterial envelope contributes to the
vital process of host–bacterial mutualism.
Materials and Methods
Bacterial Strains, Plasmids, and Media. Bacterial strains and plasmids are
described in SI Table 2.
Fig. 4. Comparison of germ-free animal colonization by B. fragilis mutants
with limited diversity of surface polysaccharides. (A) Counts of colony-forming
units (CFU) recovered from feces of germ-free animals after oral inoculation
of bacteria show the ability of both wild-type and mutant strains to colonize
laboratory animals during monoassociation. Filled squares, wild-type B. fra-
gilis 9343; open triangles, B. fragilis CPM1; open squares, B. fragilis CPM3. (B)
Percentages of each strain recovered from feces of animals after dual coloni-
zation of wild-type B. fragilis and B. fragilis CPM1 strain, premixed at a 1:1
ratio before gavage. Upon plating on selective media, wild-type bacteria
quickly outcompete CPM1. (C) Percentages of each strain recovered from
laboratory media after daily serial passages during coculture demonstrate
that CPM1 displays no growth defect in culture competition with wild-type B.
fragilis. Overnight cultures were subcultured daily into fresh media at a 1:100
dilution. (D) Percentages of each strain recovered from feces of animals after
dual colonization of CPM1 and CPM1 complemented with mpi. (E) Percent-
ages of each strain recovered from feces of animals after dual colonization of
CPM1 and CPM1 complemented with ssr3 in trans.
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Generation of Strains CPM1 and CPM2. To create the B. fragilis mpi mutant
CPM1, the plasmid pLEC80 (SI Table 2) was mobilized from DH5 cells by helper
plasmid RK231 and conjugally transferred into a B. fragilis 9343PSA mutant
strain to generate a deletion of mpi and tsr19, a tyrosine site-specific recom-
binase that is not involved in Mpi-mediated capsular polysaccharide promoter
inversion (28). Colonies selected for erythromycin resistance (Emr), indicating
integration of the suicide vector into the host chromosome, were passaged for
5 days and then plated on nonselective medium (BHI-S). The resulting colonies
were replica-plated to BHI-S containing Em, and Ems (sensitive) colonies were
screened by PCR to distinguish wild-type revertants from strains with the
desired mutation. To create mutant CPM2, a portion of the PSC locus was
deleted from CPM1 by using plasmid pMJC2.1 (SI Table 2). Complementation
studies with mpi and ssr3 were performed by cloning each gene into the B.
fragilis–Escherichia coli shuttle plasmid pFD340 (SI Table 2).
Flow Cytometry. For surface staining, cell preparations were washed twice in
ice-cold FACS buffer (PBS with 2% FBS) and resuspended in 100 l of the same
buffer. A total of 1 107 cells were incubated with rabbit polyclonal antisera
to PSB and PSC at a 1:100 dilution for 30 min at 4°C. Cells were then washed,
incubated with goat anti-rabbit fluorochrome-conjugated secondary anti-
bodies, and analyzed by flow cytometry with an FC500 cytometer.
Germ-Free Animal Colonization Experiments. Male Swiss–Webster germ-free
mice were purchased from Taconic Farms. Animals were screened for bacte-
rial, viral, and fungal contamination by Gram staining, degenerate PCR, RapID
ANA II System analysis, and plating of fecal samples under aerobic and
anaerobic conditions. Animals were housed in gnotobiotic chambers or mi-
croisolator cages, and all food and bedding were sterilized by autoclave.
Erythromycin (12.5 g/ml) and gentamicin (125 g/ml) were added to sterile
drinking water. All Bacteroides strains (naturally resistant to gentamicin)
contained the plasmid pFD340 conferring erythromycin resistance. Eight- to
13-week-old mice were orally inoculated with1 108 colony-forming units
of bacteria harvested from a log-phase culture and resuspended in PBS with
1.5% NaHCO3. At each time point after bacterial introduction to animals, fresh
fecal samples were collected, serially diluted, and plated for colony-forming
units. To discern between strains, we introduced a plasmid pFD340-cat (SI
Table 2), which confers chloramphenicol resistance. One hundred individual
colonies were patched onto BHI-S agar with erythromycin and chloramphen-
icol to determine the ratio between strains during colonization. All animals
were cared for under established protocols using Institutional Animal Care
and Use Committee guidelines of Harvard Medical School and the California
Institute of Technology.
Note added in proof. A recent report (29) shows that eight intestinal Bacte-
roidales contain multiple capsular polysaccharides, a feature not found in four
oral Bacteroidales species, suggesting that regulation of surface architecture
has evolved as a niche specific feature for intestinal organisms.
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